CA3099579A1 - Triazolopyrimidine compounds and their use in treating cancer - Google Patents

Triazolopyrimidine compounds and their use in treating cancer Download PDF

Info

Publication number
CA3099579A1
CA3099579A1 CA3099579A CA3099579A CA3099579A1 CA 3099579 A1 CA3099579 A1 CA 3099579A1 CA 3099579 A CA3099579 A CA 3099579A CA 3099579 A CA3099579 A CA 3099579A CA 3099579 A1 CA3099579 A1 CA 3099579A1
Authority
CA
Canada
Prior art keywords
methyl
triazolo
pyrrolidin
phenyl
trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099579A
Other languages
English (en)
French (fr)
Inventor
Frederick Woolf Goldberg
Attilla Kuan Tsuei Ting
Gillian McGregor LAMONT
David Buttar
Jason Grant Kettle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizal Jiangsu Pharmaceutical Co Ltd
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of CA3099579A1 publication Critical patent/CA3099579A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3099579A 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer Pending CA3099579A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11
US62/670,075 2018-05-11
PCT/EP2019/062020 WO2019215316A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CA3099579A1 true CA3099579A1 (en) 2019-11-14

Family

ID=66484070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099579A Pending CA3099579A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Country Status (16)

Country Link
US (3) US11084827B2 (cg-RX-API-DMAC7.html)
EP (2) EP3790879B1 (cg-RX-API-DMAC7.html)
JP (1) JP7418353B2 (cg-RX-API-DMAC7.html)
KR (1) KR102863374B1 (cg-RX-API-DMAC7.html)
CN (3) CN115028637B (cg-RX-API-DMAC7.html)
AR (1) AR115384A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019264826B2 (cg-RX-API-DMAC7.html)
CA (1) CA3099579A1 (cg-RX-API-DMAC7.html)
DK (1) DK3790879T3 (cg-RX-API-DMAC7.html)
ES (1) ES2927244T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020012058A (cg-RX-API-DMAC7.html)
PT (1) PT3790879T (cg-RX-API-DMAC7.html)
TW (1) TWI823932B (cg-RX-API-DMAC7.html)
UY (1) UY38228A (cg-RX-API-DMAC7.html)
WO (1) WO2019215316A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006971B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲(江蘇)醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
CA3169667A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
WO2021236893A1 (en) * 2020-05-21 2021-11-25 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2025201236A1 (zh) * 2024-03-25 2025-10-02 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途
CN121735952B (zh) * 2026-02-26 2026-07-10 山东齐都药业有限公司 维立西呱的制备方法及其中间产物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JP6612882B2 (ja) * 2015-01-22 2019-11-27 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬
WO2016118825A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Heterocyclic inhibitors of monocarboxylate transporters
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
US20190135747A1 (en) * 2016-05-12 2019-05-09 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲(江蘇)醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
DK3790879T3 (da) 2022-08-29
US12503473B2 (en) 2025-12-23
MX2020012058A (es) 2021-02-26
ZA202006971B (en) 2026-03-25
US11084827B2 (en) 2021-08-10
CN112469721A (zh) 2021-03-09
TW202015674A (zh) 2020-05-01
KR102863374B1 (ko) 2025-09-22
UY38228A (es) 2019-10-31
BR112020023068A2 (pt) 2021-02-09
KR20210013078A (ko) 2021-02-03
PT3790879T (pt) 2022-08-26
JP2021523177A (ja) 2021-09-02
CN112469721B (zh) 2022-06-07
EP3790879B1 (en) 2022-06-29
US20210340150A1 (en) 2021-11-04
ES2927244T3 (es) 2022-11-03
AR115384A1 (es) 2021-01-13
CN115028637B (zh) 2024-03-22
JP7418353B2 (ja) 2024-01-19
EP3790879A1 (en) 2021-03-17
EP4134368A1 (en) 2023-02-15
US11851432B2 (en) 2023-12-26
CN115028636A (zh) 2022-09-09
AU2019264826B2 (en) 2024-05-23
US20210087196A1 (en) 2021-03-25
CN115028637A (zh) 2022-09-09
US20240217980A1 (en) 2024-07-04
WO2019215316A1 (en) 2019-11-14
TWI823932B (zh) 2023-12-01
AU2019264826A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US12503473B2 (en) Triazolopyrimidine compounds and their use in treating cancer
AU2020252116B2 (en) Estrogen receptor degrading protacs
US9428503B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer
EP3053923B1 (en) Triazolopyrazine derivatives as tyrosin kinase inhibitors
US11034696B2 (en) Compounds for inhibiting LRRK2 kinase activity
CA3219002A1 (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
AU2026200481A1 (en) 4-(Imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives
AU2017359561A1 (en) Pyrimidinone derivatives as Cdc7 inhibitors
RU2793249C2 (ru) Триазолпиримидиновые соединения и их применение в лечении рака
HK40088382A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025B (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417B (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080418A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047024A (en) Triazolopyrimidine compounds and their use in treating cancer
KR20250100670A (ko) 융합 바이사이클릭 화합물 및 이의 Mer 및 Axl 억제제로서의 용도
CA3285578A1 (en) New e3 ubiquitin ligase ligand, protein degradation agent and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231227

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250526

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250526

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250529

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250529

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260428

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428